Clinical Significance of Vascular Endothelial Growth Factor in Patients with Lung Cancer and Tuberculous Pleurisy.
10.4046/trd.2001.50.2.171
- Author:
Byung Kook IM
;
Yoou Jung OH
;
Seung Soo SHEEN
;
Key Sung LEE
;
Kwang Joo PARK
;
Sung Chul HWANG
;
Yi Hyeong LEE
;
Jin Hyuk CHOI
;
Ho Young LIM
- Publication Type:Original Article
- Keywords:
Vascular Endothelial Growth Factor (VEGF);
Lung cancer;
Tuberculosis;
Malignant pleural effusion;
Tuberculous pleurisy
- MeSH:
Adenocarcinoma;
Carcinoma;
Carcinoma, Squamous Cell;
Enzyme-Linked Immunosorbent Assay;
Erythrocytes;
Glucose;
Humans;
L-Lactate Dehydrogenase;
Lung Neoplasms*;
Lung*;
Pleural Effusion;
Pleural Effusion, Malignant;
Tuberculosis;
Tuberculosis, Pleural*;
Tumor Burden;
Vascular Endothelial Growth Factor A*
- From:Tuberculosis and Respiratory Diseases
2001;50(2):171-181
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Angiogenesis is an essential process for the growth and metastatic ability of solid tumors. One of the key factors known to be capable of stimulating tumor angiogenesis is the vascular endothelial growth factor (VEGF). The serum VEGF concentration has been shown to be a the malignant pleural effusion showing a correlation with the biochemical parameters. The VEGF has been shown to play a role in the inflammatory diseases, but rarely in the tuberculosis (TB). The serum and pleural fluid VEGF levels were measured in patients with lung cancer and TB. Their relationship with the clinical and laboratory parameters and repeated measurement 3 months after various anticancer treatments were evaluated to assess the utility of the VEGF as a tumor marker. METHODS: Using a sandwich enzyme-linked immunosorbent assay, the VEGF concentration was measured in both sera and pleural effusions collected from a total of 85 patients with lung cancer, 13 patients with TB and 20 healthy individuals. RESULTS: The serum VEGF levels in patients with lung cancer (619.9±722.8ph/ml) were significantly higher than those of healthy controls (215.9±191.1pg/ml), However, there was no significant difference between the VEGF levels in the lung cancer and TB patients. The serum VEGF levels were higher in large cell and undifferentiated carcinoma than in squamous cell carcinoma and adenocarcinoma. The serum VEGF levels of lung cancer patients revealed no significant relationship with the various clinical parameters. The VEGF concentrations in the malignant effusion (2,228.1±2,103.0pg/ml) were significantly higher than those in the TB effusion (897.6±978.8pg/ml). In the malignant pleural effusion, the VEGF levels revealed significant correlation with the number of red blood cells (r=0.75), the lactate dehydrogenase (LDH)(r=0.70), and glucose concentration (r=-0.55) in the pleural fluid. CONCLUSION: The serum VEGF levels were higher in the lung cancer patients. The VEGF levels were more elevated in the malignant pleural effusion than in the tuberculous effusion. In addition, the VEGF levels in the pleural fluid were several times higher than the matched serum values suggesting a local activation and possible etiologic role of VEGF in the formation of malignant effusions. The pleural VEGF levels showed a significant correlation with the numbers of red blood cells, LDH and glucose concentrations in the pleural fluid, which may represent the tumor burden.
